Woodcock Defends Agency’s Accelerated Aduhelm Approval in Senate Hearing

Acting FDA Commissioner Janet Woodcock told members of the Senate Committee on Health, Education, Labor and Pensions yesterday that the FDA was simply doing what the Congress had instructed when it granted an accelerated approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab).
Source: Drug Industry Daily